You are here: Industry Insights > Hovione

News List

Hovione to create new campus and 100 jobs at New Jersey site CPhIonline
November 29, 2021
The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing.
Hovione Invests $170M to Expand Facilities Around the World ContractPharma
November 12, 2021
Hovione, a leader in spray drying and particle engineering, is expanding its industrial facilities around the world to support its growth objectives. The company has been on an expansion track...
Hovione and iBET Form Strategic Collaboration contractpharma
May 28, 2021
Contract development and manufacturing organization (CDMO) Hovione announced it has re-joined the membership of the Instituto de Biologia Experimental e Tecnológica (iBET). In 1989, Hovione was a founding member of iBET.
Hovione Launches ASD-HIPROS contractpharma
January 13, 2021
Advanced tool designed to identify optimal and commercially viable Amorphous Solid Dispersions formulation by Spray Drying.
Hovione to Support Manufacture of Remdesivir for COVID-19 contractpharma
September 24, 2020
To meet Captisol demand associated with Remdesivir, Hovione will be producing per month the quantity it usually produces in one year.
Bilim Pharmaceuticals, H&T Presspart and Hovione Collaborate contractpharma
September 02, 2020
Bilim Pharmaceuticals, H&T Presspart and Hovione are collaborating to support Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix.
Hovione Appoints Chief Operating Officer contractpharma
May 07, 2020
Dr. Jean-Luc Herbeaux joins the company from Evonik, where he held multiple high-level leadership positions over the past 20 years.
Hovione Reports Successful End-of-Phase 2 Meeting With the FDA contractpharma
September 25, 2019
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Hovione Announces Successful End-of-Phase 2 Meeting with the FDA americanpharmaceuticalreview
September 23, 2019
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Hovione Technology announces acquisition of global rights to new pulmonary inhaler device – the Papillon DPI expressbpd
April 16, 2019
Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments...

Previous page 1 2 Next page